

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG 1 4 2007

VIASYS Healthcare, GmbH C/O Ms. Yvette Lloyd Regulatory Affairs Manager VIASYS Respiratory Care, Incorporated 22745 Savi Ranch Parkway Yorba Linda, California 92887

Re: K071753

Trade/Device Name: Maserscreen Pneumo / Masterscope

Regulation Number: 868.1890

Regulation Name: Predictive Pulmonary Function Value Calculator

Regulatory Class: II Product Code: BTY Dated: August 2, 2007 Received: August 8, 2007

Dear Ms Lloyd:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal</u> Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (ii known).	V.		
Device Name:	Masterscreen Pneumo / Masterscope		
Indications for Use:			
The Masterscreen Pneumocollection of lung function volume measurements. Momeasurements will be per office or hospital. It can be cooperate in the performant The Masterscreen Pneumono energy is transferred to	parameters. The system is the system of the	stem performs cooperat COPD and Asthma patie rection of a physician in om 4 years on and older	ion-dependent flow- ents. the clinic, doctor's as long as they can
April-12-2007 Elmar Niedermeyer (Regulatory Affairs)			
Prescription Use X (Part 21 CFR 801 Subpart D)		Over-The-Counter I (21 CFR 807 Subpar	
(PLEASE DO NOT WRITE NEEDED)	BELOW THIS LINE-0	CONTINUE ON ANOTHE	ER PAGE IF
Concurrence	of CDRH, Office of De	evice Evaluation (ODE)	
" Wi	UMN		
Division Infe ction	Sign-Off) of Anesthesiology, Gene Control, Dental Devices	\$	
510(k) N	umber: <u>ko71753</u>	Pa	ge 1 of